It is biotech stocks like Cubist Pharmaceuticals (Nasdaq:CBST) that keep investors coming back into a sector that is arguably more famous for spectacular failures than reliable success. While Cubist stock has not reclaimed the highs of the 2000-2001 era, the company has nevertheless ridden the success of its antibiotic Cubicin to become a near 10-bagger from the lows of late 2002. The question for investors now, though, is whether the company can find another Cubicin and keep the investor enthusiasm healthy.
TUTORIAL: Forex Trading 101

A Solid, But Not Special, Second Quarter
Cubist reported sales growth of 5% for the second quarter, fueled by 9% growth from the company's core drug, Cubicin. Although Cubicin sales were a bit stronger than analysts were generally expecting, overall revenue was basically in line with expectations. Margin performance was likewise unspectacular in either direction - the company saw some gross margin erosion (due in part to larger sales discounts), but adjusted operating income growth tracked revenue.

The Need to Go Beyond Cubicin
At the time of its introduction in 2003, Cubicin was a big deal - one of the first really new antibiotics to hit the market in years, and one with a very different mechanism of action than the standard therapies. It was also something of an improbable success - the drug was originally discovered and developed by Eli Lilly (NYSE:LLY) but ultimately abandoned and sold to Cubist.

Cubicin has made a niche for itself as a second-line (and, in some cases, first-line) therapy for serious infections like MRSA (Methicillin-resistant Staphylococcus aureus). That said, Cubicin still competes with cheaper alternatives like generic vancomycin and branded drugs like Forest Labs' (NYSE:FRX) Teflaro and Pfizer's (NYSE:PFE) Zyvox.

While Cubist got a significant win for itself when it negotiated a settlement with Teva (Nasdaq:TEVA) that will keep Cubicin generics off the market until 2017 or 2018, the clock is still ticking.

The Pipeline
One of the leading concerns with Cubist is the relatively thin pipeline of two drugs. CXA-201 is going to head into phase three studies for urinary tract infections and complicated intraabdominal infections, and it could be a valuable gram-negative antibiotic, but it may be worth only about one-third of Cubicin in terms of market value for the stock. Even if CXA-201 shows strong efficacy in certain lung infections, the value would not rise to that of a replacement for Cubicin.

Cubist is also waiting to make a go/no-go decision on a phase three trial for CB,315 in C.diff - another serious infection with increasing issues of resistance to available drugs. Phase two results were encouraging, but do not suggest category-killer potential. Complicating matters is that clinical results for 315 seem fairly similar to those of Optimer's (Nasdaq:OPTR) Dificid - a drug that Cubist recently agreed to co-promote.

Worries About Competition and Acquisition
On one hand, Cubist benefits from the fact that antibiotics just are not a very popular area of research for large pharmaceutical companies. True, companies like AstraZeneca (NYSE:AZN) and Sanofi (NYSE:SNY) are working on some compounds, as well as smaller biotechs like Achaogen. The problem, though, is that antibiotics are difficult to develop (compounds that are good at killing living things like bacteria tend to have side effects) and the markets are not that large - antibiotic resistance is a problem, but many infections can still be handled by cheap generics, and that limits market and pricing potential.

Some shareholders also seem to be troubled by the possibility that Cubist will pursue acquisitions to fill out its pipeline and/or give its salesforce more product to sell. This concern largely comes down to one of horizon - investors who want to hold Cubist for a while should be encouraged by pipeline-filling deals (assuming reasonable valuations), while investors holding in the hopes that Cubist itself gets bought out will likely view these deals as unnecessarily risky and disruptive to deal prospects.

The Bottom Line
Cubicin is a good drug, but Cubist looks fairly priced today. An acquisition could certainly change the company's pipeline value, but it is hard to see many near-term events that would fuel a major rise in the stock price apart from an outright sale of the company to a larger drug company. (In a volatile market, domestic investing can be risky. Many investors choose to look overseas for diversification - but that strategy comes with its own risks. To learn more, see The Risks Of Investing In Emerging Markets.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Stock Analysis

    Allstate: How Being Boring Earns it Billions (ALL)

    A summary of what Allstate Insurance sells and whom it sells it to including recent mergers and acquisitions that have helped boost its bottom line.
  2. Options & Futures

    Cyclical Versus Non-Cyclical Stocks

    Investing during an economic downturn simply means changing your focus. Discover the benefits of defensive stocks.
  3. Investing Basics

    How to Deduct Your Stock Losses

    Held onto a stock for too long? Selling at a loss is never ideal, but it is possible to minimize the damage. Here's how.
  4. Economics

    Is Wall Street Living in Denial?

    Will remaining calm and staying long present significant risks to your investment health?
  5. Stock Analysis

    When Will Dick's Sporting Goods Bounce Back? (DKS)

    Is DKS a bargain here?
  6. Investing News

    How AT&T Evolved into a Mobile Phone Giant

    A third of Americans use an AT&T mobile phone. How did it evolve from a state-sponsored monopoly, though antitrust and a technological revolution?
  7. Stock Analysis

    Home Depot: Can its Shares Continue Climbing?

    Home Depot has outperformed the market by a wide margin in the last 12 months. Is this sustainable?
  8. Stock Analysis

    Yelp: Can it Regain its Losses in 2016? (YELP)

    Yelp investors have had reason to be happy recently. Will the good spirits last?
  9. Stock Analysis

    Is Walmart's Rally Sustainable? (WMT)

    Walmart is enjoying a short-term rally. Is it sustainable? Is Amazon still a better bet?
  10. Stock Analysis

    GoPro's Stock: Can it Fall Much Further? (GPRO)

    As a company that primarily sells discretionary products, GoPro and its potential falls right in line with consumer trends. Is that good or bad?
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center